Please provide your email address to receive an email when new articles are posted on . Novartis announced the FDA has granted an expanded indication for sacubitril/valsartan to lower risk for CV ...

CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less likely ...

Heart failure with reduced ejection fraction (HFrEF) is when the heart’s left ventricle can only pump out 40% or less of the blood it contains, resulting in less oxygen-rich blood being disseminated ...

Please provide your email address to receive an email when new articles are posted on . Adherence to sacubitril/valsartan was relatively good, at about 86% of prescribed patients with HF, but ...

In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although ...

Data from an open-label, fixed-sequence study showed that although sacubitril inhibited organic anion-transporting polypeptides (OATP)1B1 and OATP1B3 in vitro, this did not translate to any clinically ...

Treatment with sacubitril/valsartan, a pillar of therapy for patients with chronic heart failure with below-normal ejection fraction, came suggestively close to showing efficacy for preventing ...

Add Yahoo as a preferred source to see more of our stories on Google. Findings support sacubitril/valsartan's role as a potentially valuable late-line therapy for resistant hypertension. Credit: ABO ...

The PARADISE-MI trial comparing sacubitril/valsartan to ramipril in patients with left ventricular dysfunction after myocardial infarction (MI) and clinical heart failure led off the late-breaking ...

In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial Sacubitril leads to a greater reduction in plasma therapy NT-pro B ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when thrombotic ...